XTLB - XTL Biopharmaceuticals Ltd.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

XTL Biopharmaceuticals Ltd.

5 Badner Street
Ramat Gan 4365603
972 3 611 6600

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Joshua LevineChief Exec. OfficerN/AN/A1966
Mr. Itay WeinsteinChief Financial OfficerN/AN/A1971
Mr. Ronen Kantor AdvCompany Sec.N/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. XTL Biopharmaceuticals Ltd. has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was founded in 1993 and is headquartered in Ramat Gan, Israel.

Corporate Governance

XTL Biopharmaceuticals Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.